These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17124946)

  • 1. Risk management and monitoring methods for the future mother, embryo, fetus, and post-natal consequences.
    Jacqz-Aigrain E; Lamarque V
    Therapie; 2006; 61(4):297-304, 287-95. PubMed ID: 17124946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rationale for a post-marketing surveillance.
    Westerholm B
    Hum Reprod; 1987 Jan; 2(1):41-4. PubMed ID: 3571446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarketing analysis of medicines: methodology and value of the spanish case-control study and surveillance system in preventing birth defects.
    Martínez-Frías ML
    Drug Saf; 2007; 30(4):307-16. PubMed ID: 17408307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing surveillance: a UK/European perspective.
    Gough S
    Curr Med Res Opin; 2005 Apr; 21(4):565-70. PubMed ID: 15899105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug use during pregnancy and breast-feeding. A classification system for drug information.
    Berglund F; Flodh H; Lundborg P; Prame B; Sannerstedt R
    Acta Obstet Gynecol Scand Suppl; 1984; 126():1-55. PubMed ID: 6393685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-marketing evaluation of fertility-regulating drugs, as viewed by regulatory authorities.
    Hum Reprod; 1987 Jan; 2(1):45-58. PubMed ID: 3571447
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical assessment of drug safety].
    Imbs JL; Welsch M
    Ann Pharm Fr; 2007 Sep; 65(5):298-302. PubMed ID: 17982376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacovigilance and practical medicine. Pragmatic approach in therapeutic counseling for pregnant women].
    Demarez JP; Bégaud B
    Therapie; 1987; 42(2):223-6. PubMed ID: 3616999
    [No Abstract]   [Full Text] [Related]  

  • 12. Human experiences related to adverse drug reactions to the fetus or neonate from some maternally administered drugs.
    Shirkey HC
    Adv Exp Med Biol; 1972; 27():17-30. PubMed ID: 4140679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essentials for starting a pediatric clinical study (4): Clinical pediatric safety planning based on preclinical toxicity studies and pediatric pharmacovigilance guidance.
    Sheth N
    J Toxicol Sci; 2009; 34 Suppl 2():SP327-9. PubMed ID: 19571487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk management strategies in the postmarketing period : safety experience with the US and European bosentan surveillance programmes.
    Segal ES; Valette C; Oster L; Bouley L; Edfjall C; Herrmann P; Raineri M; Kempff M; Beacham S; van Lierop C
    Drug Saf; 2005; 28(11):971-80. PubMed ID: 16231952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which pharmacovigilance for vaccines?
    Le Louët H; Loupi E; Haramburu F;
    Therapie; 2007; 62(3):241-7. PubMed ID: 17803893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription drugs and pregnancy.
    Webster WS; Freeman JA
    Expert Opin Pharmacother; 2003 Jun; 4(6):949-61. PubMed ID: 12783591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The pharmaceutical industry and the adverse effects of the drugs].
    Lamarque V; Plétan Y
    Ann Pharm Fr; 2007 Sep; 65(5):308-14. PubMed ID: 17982378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of pharmacovigilance: a personal view.
    Edwards IR
    Eur J Clin Pharmacol; 2008 Feb; 64(2):173-81. PubMed ID: 18172624
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.